Prior to insurance coverage of multiplex tests in Japan, a systematic review of 33 Japanese studies reported that 45% of samples from patients with NSCLC of adenocarcinoma histology (2069/4619) were positive for EGFR mutation [27]. Here, EGFR is linked to non-small cell lung carcinoma.